Best Stocks Under $1.00 for 2019

The stock market has had an incredible bull-run since the Great Recession of 2008 and 2009. Stocks continue to hit new all-time highs and the price-to-earnings ratios of most S&P 500 companies look very expensive. Many investors are having trouble finding low-priced stocks that haven't already appreciated greatly during the last decade. It's hard to find a good deal on Wall Street right now when even small S&P 500 companies are trading at market caps above $1 billion.

Stocks have gotten expensive both in-terms of share price and their valuation relative to earnings. In more normal markets, a typical S&P 500 company has traded at about fifteen times their earnings. Most stocks are currently trading closer to 25 times their annual earnings. While the stock market has become more expensive as a whole, there are still a handful of undervalued stocks that are trading at less than $1.00 per share.

Value investing opportunities do exist if you're looking in the right places. Putting together a list of the best stocks under $1.00 requires investors to look at smaller and riskier companies and in sectors that are either undiscovered or unloved by the market as a whole. Some of these cheap stocks may not look especially attractive today, but long-term investors will profit if they are willing to exercise patience and hold on to shares of these comapnies through multiple economic cycles.

Some of these companies are solid investing ideas because they are too little and considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unloved and untested areas of the market. You may find even find crypto stocks, marijuana stocks and bitcoin stocks on this list. Others have been beat up by Mr. Market after a long period of slowing profits, but are now actively trying to turn around their business and bounce back. These low-priced stocks operate in a lot of different industries, but these picks all carry two common characteristics. They all have a super-low share price of $1.00 or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

#1 - Capstone Turbine (NASDAQ:CPST)

Stock Price: $0.94
Market Cap: $67.16 million
Consensus Rating: Buy
Ratings Breakdown: 3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $2.1250 (126.1% Upside)

Capstone Turbine logoCapstone Turbine Corporation develops, manufactures, markets, and services microturbine technology solutions for use in stationary distributed power generation applications worldwide. It offers microturbine units, components, and various accessories for applications, including cogeneration comprising combined heat and power (CHP) and integrated CHP, as well as combined cooling, heat, and power; and renewable energy, natural resources, and critical power supply. The company's microturbines are also used as battery charging generators for hybrid electric vehicle applications. It also provides various accessories, including rotary gas compressors with digital controls; heat recovery modules for CHP applications; dual mode controllers that allow automatic transition between grid connect and stand-alone modes; batteries with digital controls for stand-alone or dual-mode operations; batteries with digital controls; power servers for multipacked installations; protocol converters for Internet access; packaging options; and miscellaneous parts, such as frames, exhaust ducting, backflow dampers, and installation hardware. In addition, the company remanufactures microturbine engines; and provides after-market parts and services. It markets and sells its products primarily through distributors and original equipment manufacturers. Capstone Turbine Corporation was founded in 1988 and is headquartered in Van Nuys, California.
#2 - Obalon Therapeutics (NASDAQ:OBLN)

Stock Price: $0.46
Market Cap: $11.01 million
Consensus Rating: Hold
Ratings Breakdown: 2 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $2.35 (410.9% Upside)

Obalon Therapeutics logoObalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people who are obese and overweight. The company offers the Obalon balloon system designed to provide weight loss in obese patients. Obalon Therapeutics, Inc. was founded in 2008 and is headquartered in Carlsbad, California.
#3 - Aerpio Pharmaceuticals (OTCMKTS:ARPO)

Stock Price: $0.99
Market Cap: $40.09 million
Consensus Rating: Hold
Ratings Breakdown: 2 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $9.25 (834.3% Upside)

Aerpio Pharmaceuticals logoAerpio Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema. It also develops ARP-1536, a humanized monoclonal antibody that is in late stage preclinical development for the treatment of wet age-related macular degeneration; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a Phase 1a clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio.
#4 - Novavax (NASDAQ:NVAX)

Stock Price: $0.53
Market Cap: $244.87 million
Consensus Rating: Hold
Ratings Breakdown: 5 Buy Ratings, 1 Hold Ratings, 2 Sell Ratings.
Consensus Price Target: $2.9538 (457.3% Upside)

Novavax logoNovavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as allows immunization with much lower doses of antigen. The company also develops RSV F vaccine for older adults in Phase II clinical trial, and healthy children between two and six years of age in Phase I clinical trial. In addition, it develops nanoparticle vaccine candidates for clinic testing against ebola virus in Phase I clinical trial, as well as MERS coronavirus in animals; and combination respiratory vaccine to protect against influenza and RSV. The company has a clinical development agreement with Bill & Melinda Gates Foundation. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
#5 - AVEO Pharmaceuticals (NASDAQ:AVEO)

Stock Price: $0.94
Market Cap: $130.60 million
Consensus Rating: Hold
Ratings Breakdown: 3 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $2.20 (134.0% Upside)

AVEO Pharmaceuticals logoAVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase 3 TIVO-3 trial of tivozanib for the treatment of RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination with Opdivo (nivolumab), an immune checkpoint (PD-1) inhibitor, for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent hepatocyte growth factor inhibitory antibody for the treatment of squamous cell carcinoma of the head and neck, metastatic pancreatic ductal cancer, and acute myeloid leukemia; and AV-203, a potent anti-ErbB3 specific monoclonal antibody, which has completed Phase I clinical trial for treating esophageal cancer. The company's preclinical stage products include AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 for the treatment of pulmonary arterial hypertension. It has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec; and Kyowa Hakko Kirin Co., Ltd. AVEO Pharmaceuticals, Inc. has a clinical collaboration with AstraZeneca PLC to evaluate IMFINZI (durvalumab), a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.
#6 - Proteon Therapeutics (NASDAQ:PRTO)

Stock Price: $0.44
Market Cap: $9.60 million
Consensus Rating: Hold
Ratings Breakdown: 2 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $3.3333 (657.6% Upside)

Proteon Therapeutics logoProteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to improve hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.
#7 - Synergy Pharmaceuticals (NASDAQ:SGYP)

Stock Price: $0.01
Market Cap: $2.38 million
Consensus Rating: Hold
Ratings Breakdown: 1 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $7.00 (72,816.7% Upside)

Synergy Pharmaceuticals logoSynergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York. On December 12, 2018, Synergy Pharmaceuticals Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
#8 - Conatus Pharmaceuticals (NASDAQ:CNAT)

Stock Price: $0.76
Market Cap: $23.88 million
Consensus Rating: Hold
Ratings Breakdown: 1 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $5.84 (668.4% Upside)

Conatus Pharmaceuticals logoConatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company has collaboration agreement with Novartis to conduct three Phase IIb clinical trials Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.
#9 - Ideal Power (NASDAQ:IPWR)

Stock Price: $0.53
Market Cap: $9.28 million
Consensus Rating: Hold
Ratings Breakdown: 1 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $2.00 (277.4% Upside)

Ideal Power logoIdeal Power Inc. develops power conversion solutions with a focus on solar and storage, microgrid, and stand-alone energy storage applications. It operates through two Divisions, Power Conversion Systems and B-TRAN. The Power Conversion Systems Division focuses on its Power Packet Switching Architecture technology. The B-TRAN Division develops its Bi-directional bi-polar junction TRANsistor solid state switch technology. The company's principal products include 30-kilowatt(kW) power conversion systems, such as two-port and multi-port products. It also offers 30kW SunDial, a PV string inverter, which is field upgradable through the addition of a drop-in second DC port to connect batteries to a solar PV array; and The SunDial Plus, such as the PV inverter and the second DC battery port. The company sells its products primarily to systems integrators in the United States. The company was formerly known as Ideal Power Converters Inc. and changed its name to Ideal Power Inc. in July 2013. Ideal Power Inc. was founded in 2007 and is headquartered in Austin, Texas.
#10 - Achaogen (NASDAQ:AKAO)

Stock Price: $0.15
Market Cap: $10.60 million
Consensus Rating: Hold
Ratings Breakdown: 0 Buy Ratings, 9 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $10.00 (6,566.7% Upside)

Achaogen logoAchaogen, Inc., a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.
#11 - Weatherford International (NYSE:WFT)

Stock Price: $0.60
Market Cap: $587.25 million
Consensus Rating: Hold
Ratings Breakdown: 3 Buy Ratings, 10 Hold Ratings, 4 Sell Ratings.
Consensus Price Target: $1.6327 (172.1% Upside)

Weatherford International logoWeatherford International plc, an oilfield service company, provides equipment and services for the drilling, evaluation, completion, production, and intervention of oil and natural gas wells worldwide. The company operates in two segments, Western Hemisphere and Eastern Hemisphere. It offers artificial lift systems, including reciprocating rod, progressing cavity pumping, gas, hydraulic, plunger, and hybrid lift systems, as well as related automation and control systems; pressure pumping and reservoir stimulation services, such as acidizing, fracturing and fluid systems, cementing, and coiled-tubing intervention; and drill stem test tools, and surface well testing and multiphase flow measurement services. The company also provides safety, downhole reservoir monitoring, flow control, and multistage fracturing systems, as well as sand-control technologies, and production and isolation packers; liner hangers to suspend a casing string in high-temperature and high-pressure wells; cementing products, including plugs, float and stage equipment, and torque-and-drag reduction technology for zonal isolation; and pre-job planning and installation services. In addition, it offers directional drilling services, and logging and measurement services while drilling; services related to rotary-steerable systems, high-temperature and high-pressure sensors, drilling reamers, and circulation subs; managed pressure drilling, conventional mud-logging, drilling instrumentation, gas analysis, wellsite consultancy, and open hole and cased-hole logging services; reservoir solutions and software products; and intervention and remediation services. Further, the company provides equipment and drilling tools; tubular handling, management, and connection services; equipment rental services; and onshore contract drilling and related services through a fleet of land drilling and workover rigs. Weatherford International plc was incorporated in 1972 and is headquartered in Baar, Switzerland.
#12 - Sanchez Energy (NYSE:SN)

Stock Price: $0.18
Market Cap: $15.47 million
Consensus Rating: Hold
Ratings Breakdown: 0 Buy Ratings, 8 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $2.3429 (1,225.9% Upside)

Sanchez Energy logoSanchez Energy Corporation, an independent exploration and production company, focuses on the acquisition and development of U.S. onshore unconventional oil and natural gas resources. It engages in the horizontal development of resources from the Eagle Ford Shale in South Texas. It also holds an undeveloped acreage position in the Tuscaloosa Marine Shale (TMS) in Mississippi and Louisiana. As of December 31, 2017, the company had assembled approximately 285,000 net acres in the Eagle Ford Shale; and owned approximately 37,000 net acres in the TMS. Sanchez Energy Corporation was founded in 2011 and is headquartered in Houston, Texas.
#13 - New Gold (NYSEAMERICAN:NGD)

Stock Price: $0.85
Market Cap: $527.57 million
Consensus Rating: Hold
Ratings Breakdown: 0 Buy Ratings, 9 Hold Ratings, 2 Sell Ratings.
Consensus Price Target: $1.4063 (65.4% Upside)

New Gold logoNew Gold Inc., an intermediate gold mining company, engages in the development and operation of mineral properties. It primarily explores for gold, silver, and copper deposits. The company's operating properties include the Rainy River project located in Ontario, Canada; the New Afton project located near Kamloops, British Columbia, Canada; and the Cerro San Pedro mine located in the state of San Luis Potosí, Mexico. It also holds interests in the Blackwater project located to the Southwest of Prince George, British Columbia, Canada. The company was founded in 1980 and is headquartered in Toronto, Canada.
#14 - Cloud Peak Energy (NYSE:CLD)

Stock Price: $0.07
Market Cap: $5.65 million
Consensus Rating: Hold
Ratings Breakdown: 0 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $2.75 (3,626.3% Upside)

Cloud Peak Energy logoCloud Peak Energy Inc. produces coal in the Powder River Basin and the United States. The company operates through Owned and Operated Mines, and Logistics and Related Activities. It owns and operates three surface coal mines comprising the Antelope Mine and the Cordero Rojo Mine located in Wyoming; and the Spring Creek Mine located in Montana. These mines produce subbituminous thermal coal with low sulfur content. The company sells its coal primarily to domestic and foreign electric utilities. As of December 31, 2017, it controlled approximately 1.0 billion tons of proven and probable reserves. The company also has two development projects comprising the Youngs Creek project, an undeveloped surface mine project located in Wyoming; and the Big Metal project located in southeast Montana. In addition, it offers logistics and related services, including the purchase of coal from third parties, as well as the contracting and coordination of the transportation and other handling services from third-party operators. Cloud Peak Energy Inc. was founded in 1993 and is headquartered in Gillette, Wyoming.
#15 - Windstream (NASDAQ:WIN)

Stock Price: $0.24
Market Cap: $10.43 million
Consensus Rating: Hold
Ratings Breakdown: 0 Buy Ratings, 4 Hold Ratings, 3 Sell Ratings.
Consensus Price Target: $3.8717 (1,540.5% Upside)

Windstream logoWindstream Holdings, Inc. provides network communications and technology solutions in the United States. Its Consumer & Small Business segment offers services, including traditional local and long-distance voice services, and high-speed Internet services; and value-added services, such as security and online back-up. It also offers consumer video services; video entertainment service under the Kinetic brand; voice and Web conferencing products; and advanced hosted-voice, network management, and business continuity services, as well as owns and operates cable television franchises. This segment serves approximately 1.4 million residential and small business customers. The company's Enterprise segment offers integrated voice and data services, which deliver voice and broadband services over a single Internet connection, data transport services, and multi-site networking services; and other data services comprising cloud computing, and collocation and managed services as an alternative to traditional information technology infrastructure. Its Wholesale segment provides network bandwidth to other telecommunications carriers, network operators, and content providers; fiber-to-the-tower connections to support the wireless backhaul market; voice and data carrier services to other communications providers and large scale purchasers; and special access services and time division multiplexing private line transport. The company's Consumer CLEC segment offers traditional voice and long-distance services, nationwide Internet access services, and dial-up and high-speed, as well as online backup and various email services. Windstream Holdings, Inc. also leases and sells broadband modems, home networking gateways, and personal computers; and sells home phones. The company was incorporated in 2013 and is based in Little Rock, Arkansas.
#16 - Obsidian Energy (NYSE:OBE)

Stock Price: $0.35
Market Cap: $171.14 million
Consensus Rating: Hold
Ratings Breakdown: 0 Buy Ratings, 2 Hold Ratings, 2 Sell Ratings.
Consensus Price Target: $1.0833 (209.5% Upside)

Obsidian Energy logoObsidian Energy Ltd. explores for, develops, and produces oil and natural gas in western Canada. It holds interests in the Alberta Viking, Cardium, Deep Basin, and Peace River areas. The company was formerly known as Penn West Petroleum Ltd. and changed its name to Obsidian Energy Ltd. in June 2017. Obsidian Energy Ltd. was founded in 1979 and is headquartered in Calgary, Canada.
#17 - Pier 1 Imports (NYSE:PIR)

Stock Price: $0.45
Market Cap: $40.81 million
Consensus Rating: Sell
Ratings Breakdown: 0 Buy Ratings, 4 Hold Ratings, 5 Sell Ratings.
Consensus Price Target: $1.3917 (209.3% Upside)

Pier 1 Imports logoPier 1 Imports, Inc. engages in the retail sale of decorative accessories, furniture, candles, housewares, gifts, and seasonal products. It offers decorative accents and textiles, such as rugs, wall decorations and mirrors, pillows, bedding, lamps, vases, dried and artificial flowers, baskets, ceramics, dinnerware, candles, fragrances, gifts, and seasonal items; and furniture and furniture cushions that are used in living, dining, office, kitchen and bedroom areas, sunrooms, and patios. As of march 3, 2018, the Company operated 928 stores in the United States and 75 stores in Canada It also operates e-Commerce Website, pier1.com. The company was founded in 1962 and is headquartered in Fort Worth, Texas.

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel